Immatics NV

IMTX

Healthcare|Biotechnology|Germany

$9.68

-0.28 (-2.81%)

Tangible Book

$3.84

Clinical Trials (18)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06743126 SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma	Melanoma, Cutaneous Malignant	P3	Recruiting	360	RCT, Open-label	IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel
NCT03686124 ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors	Refractory Cancer, Recurrent Cancer	P1P2	Recruiting	375	Open-label	IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, Nivolumab
NCT05958121 IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors	Refractory Cancer, Recurrent Cancer	P1P2	Recruiting	400	Open-label	IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy, IMA402 and IMA401, IMA402 and monoclonal antibody, IMA402 and chemotherapy +/- monoclonal antibody
NCT06946225 ACTengine® IMA203 Combined With mRNA-4203	Cutaneous Melanoma, Synovial Sarcoma	P1	Recruiting	15	Open-label	IMA203, mRNA-4203
NCT05359445 IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor	Refractory Cancer, Recurrent Cancer	P1	Active	95	Open-label	IMA401 (Phase Ia), Pembrolizumab (Phase Ia), IMA 401 (Phase Ib)
NCT01265901 IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma	Metastatic Renal Cell Carcinoma	P3	Completed	339	RCT, Open-label	Sunitinib, GM-CSF, Cyclophosphamide, IMA901
NCT00523159 IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease	Renal Cell Carcinoma	P2	Completed	68	RCT, Open-label	Endoxana, IMA901, Leukine, IMA901 and Leukine
NCT02054884 F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma	Merkel Cell Carcinoma	P2	Terminated	13	RCT, Open-label	Arm A: F16IL2 in combination with paclitaxel, Arm B: Paclitaxel
NCT00785122 IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)	Colorectal Carcinoma	P1P2	Completed	92	Open-label	Endoxana, Leukine, IMA910, Endoxana, Leukine, IMA910, Aldara
NCT03203005 IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients	Hepatocellular Carcinoma	P1P2	Completed	22	Open-label	IMA970A plus CV8102 and Cyclophosphamide
NCT01920191 Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma	CNS Tumor, Adult	P1P2	Completed	19	Open-label	IMA 950, Poly ICLC
NCT01222221 Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	Brain and Central Nervous System Tumors	P1	Completed	45	Open-label	glioblastoma multiforme multipeptide vaccine IMA950, sargramostim, temozolomide
NCT03247309 TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)	Solid Tumor, Cancer	P1	Completed	7	Open-label	IMA201 Product
NCT01403285 Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma	Glioblastoma	P1	Terminated	6	Open-label	Cyclophosphamide, IMA950 plus GM-CSF, IMA950, Imiquimod
NCT02876510 ACTolog in Patients With Solid Cancers	Cancer, Solid Tumor	P1	Completed	38	Open-label	Fludarabine, Cyclophosphamide, IMA101 product, Recombinant human interleukin-2, Atezolizumab
NCT02149225 GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients	Glioblastoma	P1	Completed	16	Open-label	APVAC1 vaccine plus Poly-ICLC and GM-CSF, APVAC2 vaccine plus Poly-ICLC and GM-CSF
NCT03441100 TCR-engineered T Cells in Solid Tumors: IMA202-101	Solid Tumor, Adult, Refractory Cancer	P1	Completed	16	Open-label	IMA202 Product
NCT03760952 Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling	Refractory Cancer, Recurrent Cancer		Completed	242	—	—